이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

만성 염증성 탈수초 다발성 신경병증(CIDP) 환자의 정맥 내 인간 정상 면역 글로불린(IGIV) 10%를 조사한 연구

2026년 11월 4일 업데이트: Kedrion S.p.A.

만성 염증성 탈수초 다발성 신경병증(CIDP) 환자를 대상으로 인간 정상 면역 글로불린(IGIV) 10%의 두 가지 다른 투여량의 효능과 안전성을 조사하는 이중 맹검, 무작위, 다기관 연구

The current study is being conducted to assess the efficacy and safety of KIg10 (Intravenous Human Immune globulin 10%) at two different dosages as maintenance therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) following 21 weeks of treatment.

연구 개요

상태

모병

정황

개입 / 치료

상세 설명

This is a Double Blind, Randomized study. All subjects will enter a wash-out phase of up to 12 weeks, or until functional deterioration, defined as an increase of ≥1 point (worsening) in the adjusted INCAT disability score, is demonstrated. Eligible subjects will then be randomized in a 1:2 ratio to receive either 0.5 g/kg or 1.0 g/kg KIg10 at 3-weekly intervals for 21 weeks. Subjects who relapse during randomized treatment due to functional deterioration, based on the INCAT score, will be rescued with 2.0 g/kg KIg10 at 3-weekly intervals for 21 weeks.

연구 유형

중재적

등록 (추정된)

161

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

    • Connecticut
      • Stamford, Connecticut, 미국, 06905
        • 모병
        • New England Institute for Clinical Research
        • 수석 연구원:
          • Peter McAllister
    • Florida
      • Miami, Florida, 미국, 33155
        • 모병
        • Quantix Research
        • 수석 연구원:
          • Sergio Jaramillo
      • Pembroke Pines, Florida, 미국, 33024
        • 모병
        • Best Choice Medical and Research Service
        • 수석 연구원:
          • Vaniolky Losada Leon
      • Tampa, Florida, 미국, 33613
        • 모병
        • USF Health - Morsani Center for Advanced Healthcare
        • 수석 연구원:
          • Kathleen Murray
    • New Hampshire
      • Lebanon, New Hampshire, 미국, 03756
        • 모병
        • Dartmouth-Hitchcock Medical Center
        • 수석 연구원:
          • Victoria Lawson
    • Texas
      • El Paso, Texas, 미국, 79912
        • 모병
        • Advanced Neurology Epilepsy and Sleep Center/ANESC Research
        • 수석 연구원:
          • Aamr Herekar

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Male or female, aged ≥18 years.

  2. Written informed consent and authorization to access personal health information obtained independently from participants indicating that they understand the purpose of, and procedures required for, the study and are willing to participate.

  3. Documented diagnosis of CIDP consistent with the 2021 European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) criteria.

  4. Current or documented history of significant disability, as defined by an overall INCAT disability score between 2 and 9. A score of 2 must be exclusively from the lower extremities.

  5. Participants are currently dependent on treatment with immunoglobulins, corticosteroids, or standard of care treatments for CIDP.

  6. Weakness of at least two limbs.

  7. Participants should be clinically stable 12 weeks prior to screening date as defined by:

    • without a worsening in INCAT score of ≥1 point, AND/OR without significant changes in clinical symptoms AND
    • without significant dose changes or requiring additional treatments.

Exclusion Criteria:

  1. Patients' incapable of giving informed consent.

  2. Pure sensory and other CIDP variants.

  3. Females who are pregnant, breastfeeding, unwilling to practice effective birth control methods as defined in Appendix C throughout the study, or planning a pregnancy during the study.

  4. IG-experienced participants requiring an IGIV dosage of more than 1.4 g/kg/month OR SCIG pre-treated participants requiring a SCIG dosage of more than 1.6 g/kg/month.

  5. Participants who have previously failed to respond to IGIV or SCIG.

  6. On screening date, a body mass index (BMI) > 35 kg/m2 or an IGIV dose that puts the patient at risk of fluid overload.

  7. CIDP and any neuropathy of other causes not consistent with the 2021 EAN/PNS criteria including:

    1. Hereditary demyelinating neuropathies, such as a hereditary sensory and motor neuropathy (HSMN) (Charcot-Marie-Tooth [CMT] disease), and hereditary sensory and autonomic neuropathies (HSANs).
    2. Neuropathies secondary to infections, disorders, or systemic diseases such as Borrelia burgdorferi infection (Lyme disease), diphtheria, systemic lupus erythematosus, POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome, osteosclerotic myeloma, diabetic and non-diabetic lumbosacral radiculoplexopathy or neuropathy, lymphoma, and amyloidosis.
    3. Multifocal motor neuropathy (MMN).
    4. Drug-, biologic-, chemotherapy-, or toxin-induced peripheral neuropathy. Peripheral neuropathy induced by vitamin B12 deficiency.
  8. Immunoglobulin M (IgM) paraproteinemia, including IgM monoclonal gammopathy with increased titers of antibodies to myelin-associated glycoprotein.

  9. Central demyelinating disorders (e.g, multiple sclerosis) or severe myopathy.

  10. Any chronic or debilitating disease, or central nervous disorder that causes neurological symptoms or may interfere with assessment of CIDP or outcome measures (e.g., severe arthritis, stroke, Parkinson's disease, and diabetic peripheral neuropathy) [participants with clinically diagnosed diabetes mellitus, who have adequate glycemic control with Hemoglobin A1C (HbA1C) of <7.5% at screening, and who agree to maintain adequate glycemic control during the study are allowed].

  11. Congestive heart failure (New York Heart Association (NYHA) Class III/IV), unstable angina, unstable cardiac arrhythmias, or uncontrolled hypertension [i.e., diastolic blood pressure >100 mmHg and/or systolic blood pressure >160 mmHg]. If a single measure exceeds this limit, a triple repeat measurement may be performed and the average of the three measurements used.

  12. History of deep vein thrombosis or thromboembolic events (e.g, cerebrovascular accident, pulmonary embolism) in the past 12 months.

  13. Condition(s) which could alter protein catabolism and/or IgG utilization (e.g, protein-losing enteropathies, nephrotic syndrome).

  14. Known history of chronic kidney disease, or glomerular filtration rate (GFR) of <60 milliliter per minute per 1.73 square meter (mL/min/1.73m2) estimated based on an established chronic kidney disease epidemiology collaboration (CKD-EPI) equation at the time of screening.

  15. Active malignancy requiring chemotherapy and/or radiotherapy, or history of malignancy with less than 2 years of complete remission prior to screening. Exceptions are adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, and stable prostate cancer not requiring treatment.

  16. Hypersensitivity or adverse reactions (e.g, urticaria, breathing difficulty, severe hypotension, or anaphylaxis) to human blood products such as human IgG, albumin, or other blood components.

  17. Known history of immunoglobulin A (IgA) deficiency.

  18. Known history of autoimmune nodo-paranodopathies causing IG treatment resistance, including anti-neurofascin (NF) 186 antibodies and antibodies against paranodal proteins, such as NF155, contactin 1 (CNTN1), and contactin-associated protein 1 (CASPR1).

  19. Abnormal laboratory values at screening:

    1. Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 2.5x upper limit of normal (ULN)
    2. Platelet count <100,000 cells/µL.
    3. Absolute neutrophil count (ANC) <1000 cells/µL.
    4. Clinically significant anemia or hemoglobin (Hgb) level of < 10.0 g/dL at screening.
  20. Ongoing/active infection with hepatitis B virus (HBV), hepatitis C virus (HCV) or HIV Type 1/2 infection. Participants with chronic hepatitis B or hepatitis C infection currently on treatment may participate if they have undetectable viral load within 12 months of screening date.

  21. Subjects who have received:

    1. Within 2 months before wash-out phase:

      • PE
      • change in treatment of methotrexate, azathioprine, or mycophenolate
    2. Within 3 months before wash-out phase: Efgartigimod alfa (Vyvgart)

    3. Within 5 months before wash-out phase: cyclophosphamide, interferon, tumor necrosis factor-alpha inhibitors, fingolimod, or any other immunosuppressive medications

    4. Within 12 months before wash-out phase: rituximab or alemtuzumab

  22. Participants who have received a hematopoietic stem cell transplant.

  23. Participants on corticosteroids for the treatment of CIDP after being fully washed out. Participants on maintenance doses of corticosteroid may be allowed, if treatment is for conditions unrelated to CIDP (doses usually below 20 mg/day prednisone or equivalent and where the dosage is unlikely to be tapered during the duration of the trial may be allowed for indications other than CIDP).

  24. Any disorder or condition that in the investigator's judgment may impede the participant's participation in the study, pose increased risk to the participant, or confound the results of the study.

  25. Participation in another clinical study involving an investigational medicinal product (IMP) or investigational device within 30 days prior to screening visit or within 5 half-lives of the IMP under investigation or is scheduled to participate in another clinical study involving an IMP or investigational device during the intended course of this study.

  26. History of acquired or inherited thrombophilic disorders. These will include the specific types of acquired or inherited thrombophilic disorders that could put participants at risk of developing thrombotic events. Examples include, but are not restricted to:

    1. Hereditary thrombophilia, examples include

      • Factor V Leiden mutation.
      • Prothrombin 20210A mutation.
      • Protein C deficiency.
      • Protein S deficiency.
      • Antithrombin deficiency.
    2. Acquired thrombophilias, examples include:

      • Antiphospholipid antibody syndrome.
      • Activated protein C Resistance acquired.
      • Homocysteinemia.
  27. Previous participation in this clinical study, except for participants who withdrew consent during the washout phase, prior to randomization.

  28. Any other factor that, in the opinion of the investigator, would prevent the subject from complying with the requirements of the protocol.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 더블

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: 1.0 g/kg dose group for 24 weeks

This group will receive, initial loading dose of 2.0 g/kg of Intravenous (IV) KIg10 (Immunoglobulin) infusion followed by 1.0 g/kg of IV KIg10 every 3 weeks.

Kedrion intravenous immunoglobulin (IVIg) 10%

다른 이름들:
  • KIg10
실험적: 0.5 g/kg dose group for 24 weeks

This group will receive, Initial loading dose of 2.0 g/kg of Intravenous (IV) KIg10 (Immunoglobulin) infusion will be given followed by 0.5 g/kg of IV KIg10 every 3 weeks.

Kedrion intravenous immunoglobulin (IVIg) 10%

다른 이름들:
  • KIg10

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Efficacy of 1.0 g/kg KIg10 in the treatment of adult subjects with active CIDP
기간: From Baseline upto 24 weeks of treatment

The proportion of responders in the 1.0 g/kg KIg10 arm, at week 24 relative to Randomization Baseline week 0, based on the adjusted INCAT disability score. A responder is defined as having a ≥1 point decrease (improvement) in the adjusted INCAT score at week 24 relative to adjusted INCAT score at randomization baseline.

From Baseline upto 24 weeks of treatment

2차 결과 측정

결과 측정
측정값 설명
기간
Efficacy of 0.5 g/kg KIg10 in the treatment of adult subjects with active CIDP
기간: From Baseline upto 24 weeks of treatment

The proportion of responders in the 0.5 g/kg KIg10 arm at week 24 relative to randomization baseline, based on the adjusted INCAT disability score. A responder is defined as having a ≥1 point decrease (improvement) in the adjusted INCAT score at week 24 relative to adjusted INCAT score at randomization baseline.

From Baseline upto 24 weeks of treatment
Proportion of responders (Week 24 vs Baseline) in both dose groups
기간: From Baseline upto 24 weeks of treatment

Proportion of responders in both dose groups based on Grip Strength and I-RODs

From Baseline upto 24 weeks of treatment
Proportion of responders in rescued subjects
기간: End of Treatment vs onset of rescue treatment

Proportion of responders in rescued subjects based on grip strength, I-RODS scores, adjusted INCAT disability score

End of Treatment vs onset of rescue treatment
Improvers based on the MRC-sumscore
기간: From Baseline upto 24 weeks of treatment

Improvers by a change of 4 points in both dose groups (week 24 versus baseline) based on MRC-sumscore

From Baseline upto 24 weeks of treatment
Mean Change in MRC-sumscore
기간: From Baseline upto 24 weeks of treatment

Mean change in MRC-sumscore for both dose groups at week 24 vs baseline

From Baseline upto 24 weeks of treatment
Mean Change in MRC-sumscore for rescued subjects
기간: End of Treatment vs onset of rescue treatment

Mean change in MRC-sumscore for rescued subjects from End of Treatment versus onset of rescue treatment

End of Treatment vs onset of rescue treatment
Disease Related QoL (CAPPRI) for each dose level
기간: From Baseline upto 24 weeks of treatment

For each dose level the Chronic Acquired Polyneuropathy Patient Reported Index (CAPPRI) will be analysed for disease related QoL

From Baseline upto 24 weeks of treatment
Mean change in I-RODS
기간: From Baseline upto 24 weeks of treatment

For each dose level, mean change from randomization baseline (visit 2, week 0) to end of study (visit 10, week 24) in Inflammatory-Rasch-built Overall Disability Scale (I- RODS) score

From Baseline upto 24 weeks of treatment
Mean change in I-RODS for rescued subjects
기간: End of Treatment vs onset of rescue treatment

Mean change to the end of treatment assessments prior to onset of rescue treatment, in Inflammatory-Rasch-built Overall Disability Scale (I- RODS) score for rescued subjects

End of Treatment vs onset of rescue treatment

기타 결과 측정

결과 측정
측정값 설명
기간
Number of adverse events
기간: From Baseline upto 25 weeks

Assess Safety and Tolerability of KIg10

From Baseline upto 25 weeks
The proportion of patients experiencing at least one adverse event.
기간: From Baseline upto 25 weeks

Assess Safety and Tolerability of KIg10

From Baseline upto 25 weeks

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 연구 의자: Lakshmi Deshpande, Kedrion S.p.A.

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 11월 1일

기본 완료 (추정된)

2027년 12월 20일

연구 완료 (추정된)

2027년 12월 27일

연구 등록 날짜

최초 제출

2024년 12월 16일

QC 기준을 충족하는 최초 제출

2024년 12월 27일

처음 게시됨 (실제)

2024년 12월 30일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 5일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 4일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • KB071
  • KB071 (기타 식별자: Kedrion S.p.A)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

IPD 계획 설명

Publishing of data and IPD that underlie results in the publication will be determined at study completion to comply with ICJME minimum requirements.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .